Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice TargetHot
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $780 to $982.
Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $780 to $982.